Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
|
23812671 |
2013 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Microsatellite instability: an update.
|
25701956 |
2015 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
|
20857202 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These findings do not support testing stage I or II colorectal tumors for BRAF mutations, although additional large studies are needed.
|
29660527 |
2019 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms.
|
15729718 |
2005 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, 40 wild type KRAS and BRAF colorectal tumors were analyzed to elucidate whether PML-RARa bcr1 fusion gene may play a role in colorectal carcinogenesis.
|
22167334 |
2012 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
|
18757341 |
2008 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.
|
19794125 |
2009 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor, we selected 75 samples previously characterized by conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution Melting analysis and direct sequencing.
|
23536897 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer.
|
17195912 |
2007 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The LR in favor of pathogenicity was estimated to be ~12-fold for a colorectal tumor with a BRAF mutation-negative MSI-H phenotype.
|
22949379 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF as a target for cancer therapy.
|
21426297 |
2011 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation.
|
29127628 |
2019 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Vemurafenib doesn't shrink BRAF-mutated colorectal tumors, but a regimen that also includes irinotecan and cetuximab improves vemurafenib's effectiveness, more than doubling progression-free survival in patients with metastatic tumors.
|
28153858 |
2017 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer.
|
15765445 |
2005 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We did not detect BRAF mutations in patients with double somatic colorectal tumors or Lynch syndrome.
|
27302833 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR).
|
14668801 |
2003 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
|
25517872 |
2015 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
|
22180495 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
|
21163703 |
2011 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
|
25239454 |
2014 |